??

Drug Resistance Models in Mice: Mechanisms, Establishment and Applications

Overcoming Obesity: Challenges Facing Weight Loss Drugs and the Promise of Combination Therapies

Developing Robust Preclinical Evaluation Strategies for T-Cell Engagers (TCEs): Accelerating Development and Reducing Translational Risks

Accelerating TCE Drug Development with Humanized Mouse Models

T-cell engagers (TCEs) are innovative bispecific antibodies designed to bind simultaneously to tumor-associated antigens (TAAs) and the CD3 receptor on T-cells. Several TCE drugs have already been approved, with seven bispecific antibodies targeting indications such as multiple myeloma and diffuse large B-cell lymphoma (DLBCL), focusing on markers like BCMA, GPRC5D, CD20, and CD19. In the realm of solid tumors, two TCE bispecific antibodies have received approval: Tebentafusp (Immunocore, January 2022, targeting CD3×GP100) and Tarlatamab (Amgen, May 2024, targeting CD3×DLL3). The accelerated approval of Tarlatamab has spurred increased interest in TCE bispecific antibodies for drug development in the solid tumor space. However, significant unmet clinical needs remain, especially for TCE bispecific antibodies targeting solid tumors.

To address this gap, GemPharmatech has established a comprehensive preclinical pharmacology and efficacy evaluation platform, offering a range of in vivo tumor models to support the development of TCE-based therapies.

Mouse Models for Studying Anti-PD-1 Resistance

GemPharmatech Launches New Site and Research Platform in Shanghai Baoshan Base

GemPharmatech and Charles River Laboratories Sign Exclusive Agreement to Distribute Next Generation NCG Portfolio

GemPharmatech, Leading Provider of Genetically Engineered Mouse Models, Goes Public on Shanghai Stock Exchange

Recent Publication in Mammalian Genomics